HQ CDMO Bora health
  • 中文
  • News & Events
  • Investors
  • Careers
  • Sustainable Development

Bora Pharmaceuticals

Contact
  • CDMO
  • R & D
  • Facilities
    • Mississauga Facility
    • Zhunan Facility
    • Tainan Facility
  • About
  • Our Business
    • Consumer Healthcare & OTC
    • Prescription Drugs
    • Partnering



Corporate Governance

Audit Committee

  • Corporate Governance
    • Board of Director
      • Board Member
      • Resolution Item
    • Audit Committee
      • Audit Committee Member
      • Implementation
    • Compensation Committee
      • Compensation Committee Member
    • Corporate Governance Function
      • Board of Director Performance Evaluation
      • Ethical Corporate Policy
    • Evaluation on Auditor’s Independence
  • Financials
    • Monthly Revenue
    • Annual Reports
  • Stakeholder
    • List of Main Stakeholders
  • Shareholder Services
    • Dividends

Resolution for each year’s meeting are as follows. (For Company’s each year meeting attendance rate, please refer to the Company’s respective annual report.)

  • 2021

    Date of convening

    Discussion items

    Resolution

    2021.03.30 2020 (2nd) 5th Audit Committee Meeting

    Agenda Item 1: The Company’s “2020 Statement on Internal Control”.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Review the Company's independent assessment of certified public accountants

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: 2020 Business Operation Report and Financial Statements.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 5: Proposal to distribute new shares for capital increase by earnings.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 6: Propose to continue to provide a loan guarantee of NT$30 million to Bora Pharmaceutical Laboratories Inc., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 7: Propose to continue to provide a loan guarantee of NT$20 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 8: Propose to continue to provide a loan guarantee of NT$20 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 9: Propose to continue to provide a loan guarantee of NT$60 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    2021.05.13 2020 (2nd) 6th Audit Committee Meeting

    Agenda Item 1: Propose to provide a credit purchase guarantee to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Amendment of the Company’s written internal control system.

    Unanimously approved by all attending Audit Committee members

    2021.06.14 2020 (2nd) 7th Audit Committee Meeting

    Agenda Item 1: Propose to discharge the non-compete clause for directors.

    Unanimously approved by all attending Audit Committee members

    2021.08.11 2020 (2nd) 8th Audit Committee Meeting

    Agenda Item 1: Propose to continue to provide a loan guarantee to Bora Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Propose to provide a credit purchase guarantee to Bora Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: Propose to continue to provide a loan guarantee to Bora Pharmaceutical Laboratories Inc. Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 4: Amendment to the Company’s 2021 Internal Audit Plan.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 5: Appointment of the Company’s internal audit manager.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 6: Propose to issue employee stock warrants to non-managers

    Unanimously approved by all attending Audit Committee members

  • 2020

    Date of convening

    Discussion items

    Resolution

    2020.01.08 2020 (1st) 7th Audit Committee Meeting

    Agenda Item 2: Propose to provide a loan guarantee of NT$30 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    2020.03.09 2020 (1st) 8th Audit Committee Meeting

    Agenda Item 1: The Company’s “2019 Statement on Internal Control”.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Review the Company's independent assessment of certified public accountants

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: 2019 Business Operation Report and Financial Statements.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 5: Proposal to distribute new shares for capital increase by earnings.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 6: Amendments to the Procedures for Extending Loans to Others:

    Unanimously approved by all attending Audit Committee members

    Agenda Item 7: Amendment to the Procedures for Lending Funds to Other Parties.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 8: Propose to provide endorsements and guarantees to the Company’s 100% owned Canadian subsidiary.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 9: Proposal for acquisition of the Canadian facility of GlaxoSmithKline Inc. (GSK).

    Unanimously approved by all attending Audit Committee members

    Agenda No.10: Amendment of the cycle procedures of the Company’s internal control system

    Unanimously approved by all attending Audit Committee members

    2020.05.13 2020 (1st) 9th Audit Committee Meeting

    Agenda Item 1: Propose to provide a new loan guarantee of NT$20 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Propose to provide a loan guarantee of NT$20 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: Propose to provide a loan guarantee of NT$50 million to Bora Pharmaceutical Laboratories Inc., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 4: Formulated “Procedures for Treasury Stock Repurchase”.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 5: Propose to increase capital for Canadian subsidiary.

    Unanimously approved by all attending Audit Committee members

    2020.08.06 2020 (2nd) 1st Audit Committee Meeting

    Agenda Item 2: Propose to provide a loan guarantee to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: Propose to provide a loan guarantee to Bora Pharmaceutical Laboratories Inc., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 4: Establish the Company’s internal control management.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 5: US subsidiary capital increase.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 6: Propose to provide guarantee (hereinafter referred to as the "Guarantee") for the Company’s Canadian subsidiary, Bora Pharmaceuticals Services Inc. (hereinafter referred to as “borrower”), in applying for a syndicated loan led by CTBC Bank, of a total credit limit of CAD 75 million (hereinafter referred to as the “Loan”), and together sign a mortgage deed (hereinafter referred to as the “Mortgage Deed”) and pledge all the shares of the borrower held by the Company to provide guarantee (hereinafter referred to as the "Stock Pledge").

    Unanimously approved by all attending Audit Committee members

    2020.10.21 2020 (2nd) 2nd Audit Committee Meeting

    Agenda Item 1: Propose to issue employee stock warrants.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 2: Amendment of “Procedures for Treasury Stock Repurchase”.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: Propose to provide a loan guarantee to Bora Pharmaceutical Laboratories Inc., a company that is 100% owned by the Company, for its loan extension.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 4: Propose to continue to provide a loan guarantee of NT$20 million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

    2020.11.12 2020 (2nd) 3rd Audit Committee Meeting

    Agenda Item 1: Propose to extend a loan to Canadian subsidiary, Bora Pharmaceuticals Services Inc.

    Unanimously approved by all attending Audit Committee members

    Agenda Item 3: Amendment of “2020 First Employee Stock Warrants Issuance and Terms and Conditions”.

    Unanimously approved by all attending Audit Committee members

    2020.12.29 2020 (2nd) 4th Audit Committee Meeting

    Agenda Item 1: Propose to continue to provide a loan guarantee of NT$30million to Yuta Health Co., Ltd., a company that is 100% owned by the Company.

    Unanimously approved by all attending Audit Committee members

Related content:
  • Corporate Governance
  • Financials
  • Stakeholder
  • Shareholder Services
  • Share

Bora Pharmaceuticals

  • Home
  • Our Business
  • R & D
  • Facilities
  • About
  • Partnering
  • News & Events
  • Investors
  • Careers

© 2022 Bora Pharmaceuticals